Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)
NCT ID: NCT01030835
Last Updated: 2017-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
5000 participants
OBSERVATIONAL
2009-05-28
2012-04-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
\- The National Institute of Drug Abuse (NIDA) is interested in developing a pool of potential research participants who may be eligible for research studies on drug abuse and addiction, pharmacological and psychosocial therapies for substance addiction, drug abuse and co-occurring psychiatric disorders, and the long-term effects of drugs on the development, function, and structure of the brain and other organ systems. To develop this pool of potential participants, researchers intend to screen individuals who may be eligible for future research studies.
Objectives:
\- To identify, recruit, and screen participants for NIDA collaborative research protocols.
Eligibility:
\- Individuals 18 years of age and older who are able to provide informed consent.
Design:
* Eligible participants will undergo two screening interviews: a telephone interview and an in-person interview. The phone interview will determine eligibility for the in-person interview.
* The in-person interview, which may require up to five visits to the clinical center, will involve any or all of the following procedures: (1) full physical examination and medical history; (2) psychiatric interview; (3) psychological testing; (4) electrocardiogram; (5) samples of blood, urine, and hair; and (6) other minimally invasive procedures as directed by the research staff.
* Participants will provide a photograph for confirmation of identity for subsequent visits and protocols.
* No clinical care will be provided under this protocol.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Pilot, Proof-of-concept Cohort Study of the Prevalence of Comorbid Mental Illness and Substance Abuse
NCT02476877
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
NCT06349083
Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRP
NCT06552741
Psilocybin-Assisted Therapy for Severe Alcohol Use Disorder
NCT06160232
Outcome Inference in the Sensory Preconditioning Task in Opioid-Use Disorder
NCT03745339
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The screening process will be done in two stages, a telephone interview and an in-person evaluation. The telephone interview will last approximately 20 minutes and be conducted solely via the NIDA call center. Answers provided during the phone interview will indicate whether a caller is eligible for in-person screening. Those who appear eligible will be given an appointment at either NIDA or MPRC. This protocol pertains only to the in-person participants at MPRC. Written informed consent will be obtained when the person arrives. The screening process can involve up to 5 visits to MPRC.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Ability to understand and answer the questions posed
Exclusion Criteria
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Drug Abuse (NIDA)
NIH
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David A Gorelick, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Institute on Drug Abuse (NIDA)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institute on Drug Abuse, Biomedical Research Center (BRC)
Baltimore, Maryland, United States
Maryland Psychiatric Research Center (MPRC) 55 Wade Avenue
Catonsville, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
09-DA-N444
Identifier Type: -
Identifier Source: secondary_id
999909444
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.